Caribou Biosciences تقدم تحديثات حول علاجات CAR-T في مؤتمر للرعاية الصحية

16 مايو، 2026

من إعداد الذكاء الاصطناعي

ناقشت شركة Caribou Biosciences التقدم المحرز في علاجاتها الجاهزة من نوع CAR-T خلال عرض تقديمي في مؤتمر بنك أوف أمريكا العالمي للرعاية الصحية في 13 مايو. وسلطت الرئيسة التنفيذية راشيل هورويتز الضوء على بيانات المرحلة الأولى لبرنامجين يستهدفان الأورام اللمفاوية والورم النقوي المتعدد.

تعمل الشركة على تطوير علاج Vispa-cel، الذي يستهدف مستضد CD19 للأورام اللمفاوية، وعلاج CB-011، الذي يستهدف مستضد BCMA للورم النقوي المتعدد. وأشارت هورويتز خلال الجلسة التي أدارها المحلل أليك ستراناان إلى أن كلا البرنامجين تلقيا تحديثات سريرية هامة في أواخر العام الماضي، وأن النتائج الأولية تدعم احتمالية كونهما الأفضل في فئتهما.

CAR-T therapy achieves complete remission of three autoimmune diseases in German woman

9 أبريل، 2026 من إعداد الذكاء الاصطناعي صورة مولدة بواسطة الذكاء الاصطناعي

A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.

Engineered antibody shrinks tumors body-wide in early cancer trial

Researchers tested a redesigned CD40 agonist antibody, 2141-V11, by injecting it directly into tumors of 12 patients with metastatic cancers. Six patients saw tumor shrinkage, with two achieving complete remission, including effects on untreated tumors elsewhere in the body. The trial reported only mild side effects, unlike prior CD40 therapies.

AbCellera Biologics publishes Q4 2025 earnings call presentation

24 فبراير، 2026 من إعداد الذكاء الاصطناعي

AbCellera Biologics Inc. has released a slide deck related to its fourth-quarter 2025 results. The presentation accompanies the company's earnings call. It was published on February 24, 2026.

أعمال

Sutro Biopharma presents at World ADC London Summit

أعمال

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

أعمال

Syntara reports positive FDA feedback on amsulostat trial

Scientists develop antibodies to block widespread Epstein-Barr virus

Researchers at Fred Hutch Cancer Center have created human-like monoclonal antibodies that prevent Epstein-Barr virus (EBV) from infecting immune cells. Using mice engineered with human antibody genes, the team identified antibodies targeting viral proteins gp350 and gp42, with one fully blocking infection in lab models. The findings, published in Cell Reports Medicine, could lead to therapies for transplant patients at risk of EBV-related complications.

Researchers launch BRIDGE project on aggressive breast cancer

12 أبريل، 2026 من إعداد الذكاء الاصطناعي

Scientists from ITQB NOVA and the Portuguese Institute of Oncology have started the BRIDGE project to uncover how aggressive breast cancer evades the immune system. The initiative seeks biomarkers for better prediction of disease progression and personalized treatments. Funded with up to €75,000, the two-year effort uses patient samples to validate lab findings.

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

A Japanese health panel has approved national health insurance coverage for Sumitomo Pharma's Amchepry, an iPS cell-derived treatment for Parkinson’s disease. The move makes it the world's first commercialized medical product from iPS cells.

Nuvation Bio holds Q1 2026 earnings call

4 مايو، 2026 من إعداد الذكاء الاصطناعي

Nuvation Bio Inc. conducted its first quarter 2026 earnings call on May 4, 2026. The company reviewed financial results for the period ending March 31, 2026, and provided a business update. Executives including CEO David Hung participated in the discussion.

15 مايو 2026 11:05

Caribou Biosciences تقدم تحديثات حول علاجات CAR-T في مؤتمر للرعاية الصحية

مقالات ذات صلة

CAR-T therapy achieves complete remission of three autoimmune diseases in German woman

Engineered antibody shrinks tumors body-wide in early cancer trial

AbCellera Biologics publishes Q4 2025 earnings call presentation

Sutro Biopharma presents at World ADC London Summit

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Syntara reports positive FDA feedback on amsulostat trial

Scientists develop antibodies to block widespread Epstein-Barr virus

Researchers launch BRIDGE project on aggressive breast cancer

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

Nuvation Bio holds Q1 2026 earnings call

Stiffening cancer cells boosts car t-cell therapy in mice

Arrowhead pharmaceuticals ceo stresses dual r&d and commercial focus

Pulse Biosciences presents ablation technology at healthcare conference

Study confirms tenth HIV cure case via stem cell transplant

Canadian researchers uncover brain cells fueling glioblastoma growth

AI identifies breast cancer drug for multiple viruses

CK Life unit Sequencio eyes China fast track for cancer vaccines

Evaxion reports improved 2025 financials and transformational clinical progress

Researchers advance two-part therapy for type 1 diabetes

Chinese team reports scalable way to generate large batches of engineered NK cells from cord-blood stem cells

يستخدم هذا الموقع ملفات تعريف الارتباط